Back

Diabetes Might Shape Vasculature, Tumor Dissemination and Circulating Inflammation Marker Profiles in Prostate Cancer.

Kowalski, K.; Popeda, M.; Richert, J.; Wenta, R.; Szade, J.; Zaczek, A.; Kryczka, T.; Frankiewicz, M.; Miszewski, K.; Matuszewski, M.; Bednarz-Knoll, N.

2026-04-29 cancer biology
10.64898/2026.04.27.720986 bioRxiv
Show abstract

Background and objectiveChronic comorbidities like diabetes mellitus can influence cancer incidence and progression. However, their impact on pathological and molecular tumor characteristics, and dissemination, especially in prostate cancer (PCa), is not fully understood. Here, we investigated differences in the PCa molecular landscape with coexisting diabetes type 2 and its link to tumor dissemination. MethodsDAmico intermediate- or high-risk PCa patients (n=145), with type 2 diabetes or no diabetes, were analyzed for clinico-pathological features, circulating tumor cell (CTC) presence, yields and phenotypes in tumor-draining vein (TDVB) and peripheral blood (PB), primary tumor characteristics, and selected plasma biomarkers. Key findings and limitationsDiabetes type 2 was found in 20/13.8% patients and associated with more advanced clinical outcomes, i.e. pathological tumor stage (p=0.011) and lymph node involvement (p=0.020). Among patients diagnosed before age 65, diabetes and PCa showed a borderline association with shorter time-to-biochemical recurrence (p=0.032). Diabetic PCa patients had significantly higher total CTC counts in TDVB but not in PB, indicating enhanced tumor cell dissemination from primary tumor (PT). PTs from diabetic PCa patients displayed a borderline association with higher ALDH1 expression (p=0.054) and significantly lower vascular vessel density (p=0.008). Similarly, in patients under 65, PTs from diabetic PCa patients expressed genes linked to decreased angiogenesis. Plasma analyses revealed elevated GDF15 levels in PB (p<0.001), increased TRAP5 concentrations in TDVB (p=0.001), and reduced osteonectin levels in TDVB (p=0.026) in diabetic PCa patients. The studys limitation is the relatively small cohort, especially those with coexisting diabetes type 2. Conclusion and clinical implicationsDiabetes in PCa patients associates with advanced tumor stage, enhanced tumor cell dissemination, impaired vascularization, and distinct circulating biomarker alterations. Vascular alterations from diabetes, with systemic factors, especially in PCa patients under 65, may increase tumor dissemination in PCa. However, exact mechanisms need investigation in larger cohorts of patients. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=134 SRC="FIGDIR/small/720986v1_ufig1.gif" ALT="Figure 1"> View larger version (58K): org.highwire.dtl.DTLVardef@1f5047forg.highwire.dtl.DTLVardef@fa3f43org.highwire.dtl.DTLVardef@14f7765org.highwire.dtl.DTLVardef@27a12d_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Frontiers in Oncology
95 papers in training set
Top 0.1%
14.5%
2
PLOS ONE
4510 papers in training set
Top 26%
6.4%
3
International Journal of Cancer
42 papers in training set
Top 0.1%
6.4%
4
Cancers
200 papers in training set
Top 0.8%
6.4%
5
British Journal of Cancer
42 papers in training set
Top 0.2%
4.9%
6
Scientific Reports
3102 papers in training set
Top 23%
4.9%
7
The Prostate
11 papers in training set
Top 0.1%
4.9%
8
Journal of Translational Medicine
46 papers in training set
Top 0.1%
4.0%
50% of probability mass above
9
Frontiers in Endocrinology
53 papers in training set
Top 0.6%
3.3%
10
Cells
232 papers in training set
Top 1%
2.1%
11
BMC Cancer
52 papers in training set
Top 1.0%
2.1%
12
PeerJ
261 papers in training set
Top 5%
1.9%
13
Molecular Oncology
50 papers in training set
Top 0.4%
1.7%
14
Clinical Epigenetics
53 papers in training set
Top 0.5%
1.7%
15
The Journal of Pathology
22 papers in training set
Top 0.2%
1.5%
16
iScience
1063 papers in training set
Top 21%
1.2%
17
Oncogene
76 papers in training set
Top 1%
1.2%
18
Medicine & Science in Sports & Exercise
15 papers in training set
Top 0.3%
1.0%
19
eBioMedicine
130 papers in training set
Top 3%
0.9%
20
Nature Communications
4913 papers in training set
Top 60%
0.9%
21
eLife
5422 papers in training set
Top 53%
0.9%
22
Cancer Research Communications
46 papers in training set
Top 0.9%
0.9%
23
Modern Pathology
21 papers in training set
Top 0.4%
0.8%
24
Frontiers in Pharmacology
100 papers in training set
Top 4%
0.8%
25
Molecular & Cellular Proteomics
158 papers in training set
Top 2%
0.8%
26
Frontiers in Immunology
586 papers in training set
Top 8%
0.7%
27
Computational and Structural Biotechnology Journal
216 papers in training set
Top 11%
0.7%
28
ACS Pharmacology & Translational Science
40 papers in training set
Top 1%
0.5%
29
Heliyon
146 papers in training set
Top 9%
0.5%
30
Evolutionary Applications
91 papers in training set
Top 2%
0.5%